ES8205399A1 - Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas - Google Patents

Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas

Info

Publication number
ES8205399A1
ES8205399A1 ES498337A ES498337A ES8205399A1 ES 8205399 A1 ES8205399 A1 ES 8205399A1 ES 498337 A ES498337 A ES 498337A ES 498337 A ES498337 A ES 498337A ES 8205399 A1 ES8205399 A1 ES 8205399A1
Authority
ES
Spain
Prior art keywords
ring
groups
heterocyclic
saturated
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES498337A
Other languages
English (en)
Other versions
ES498337A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nyegaard and Co AS
Original Assignee
Nyegaard and Co AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyegaard and Co AS filed Critical Nyegaard and Co AS
Publication of ES8205399A1 publication Critical patent/ES8205399A1/es
Publication of ES498337A0 publication Critical patent/ES498337A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE 5-HALOPRIMIDIN-2-ONAS Y DE SUS SALES FISIOLOGICAMENTE COMPATIBLES, DE FORMULA (I), EN LA QUE X ES UN HALOGENO; R1 Y R2 SON HIDROGENO O ALCOHILO C1-4; ALC ES UN RADICAL HIDROCARBILO ALIFATICO, DIVALENTE, Y HET ES UN ANILLO HETEROCICLICO DE 3 A 9 ESLABONES. CONSISTE EN LA REACCION DE CONDENSACION DE UN COMPUESTO DE FORMULA (II), EN LA QUE X, R1 Y R2 SON LOS MISMOS QUE EN LA FORMULA (I), O UNA DE SUS SALES, CON UN AGENTE CAPAZ DE INTRODUCIR EL GRUPO HET-ALC-, TAL COMO UN DERIVADO HALOGENADO, O TIPO ESTER, DEL MISMO. LA REACCION SE LLEVA A CABO EN AUSENCIA DE AGUA, A PH ALCALINO Y EN PRESENCIA DE UN AGENTE DE CONDENSACION, TAL COMO UN ACETAL DE UNA DIALCOHILFORMAMIDA C1-5.
ES498337A 1980-01-07 1981-01-05 Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas Granted ES498337A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8000381 1980-01-07

Publications (2)

Publication Number Publication Date
ES8205399A1 true ES8205399A1 (es) 1982-06-01
ES498337A0 ES498337A0 (es) 1982-06-01

Family

ID=10510470

Family Applications (2)

Application Number Title Priority Date Filing Date
ES498337A Granted ES498337A0 (es) 1980-01-07 1981-01-05 Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas
ES509219A Granted ES509219A0 (es) 1980-01-07 1982-02-01 "un procedimiento para la preparacion de 5-halopirimidin-2-onas".

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES509219A Granted ES509219A0 (es) 1980-01-07 1982-02-01 "un procedimiento para la preparacion de 5-halopirimidin-2-onas".

Country Status (13)

Country Link
US (1) US4399140A (es)
EP (1) EP0032131B1 (es)
JP (1) JPS56150087A (es)
AT (1) ATE4715T1 (es)
AU (1) AU543939B2 (es)
CA (1) CA1168239A (es)
DE (1) DE3160886D1 (es)
DK (1) DK149892B (es)
ES (2) ES498337A0 (es)
IE (1) IE50765B1 (es)
NO (1) NO810024L (es)
NZ (1) NZ195947A (es)
ZA (1) ZA8164B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1160226A (en) * 1980-07-15 1984-01-10 Gordon H. Phillipps Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, pharmaceutical compositions containing them and a method therefor
NZ197715A (en) * 1980-07-15 1984-12-14 Glaxo Group Ltd Substituted pyrimin-2-ones and pharmaceutical compositions
DE3270525D1 (en) * 1981-01-09 1986-05-22 Nyegaard & Co As Substituted pyrimidin-2-ones and the salts thereof
ES8403879A1 (es) * 1982-02-24 1984-04-01 Nyegaard & Co As Un procedimiento para la preparacion de pirimidin-2-onas sustituidas.
SU1235864A1 (ru) * 1983-03-11 1986-06-07 Отделение ордена Ленина института химической физики АН СССР Нитроксильные производные 5-фторурацила,обладающие противоопухолевой активностью
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
US20160002204A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
PT3164394T (pt) 2014-07-03 2020-05-08 Univ Texas Inibidores gls1 para o tratamento de doenças
WO2017004359A1 (en) 2015-06-30 2017-01-05 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
US10150753B2 (en) 2015-12-22 2018-12-11 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833586A (en) * 1971-03-25 1974-09-03 Morton Norwich Products Inc 1-(substituted benzyl)-2-(1h)pyrimidones and 1-(substituted benzyl)tetrahydro-2-(1h)pyrimidones
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4003900A (en) * 1976-03-11 1977-01-18 Morton-Norwich Products, Inc. 1-Benzyl-5-chloro-2-(1H)-pyrimidone
US4052399A (en) * 1976-09-13 1977-10-04 Morton-Norwich Products, Inc. 1-[2-(Hexahydro-1H-azepino)ethyl]-2(1H)pyrimidone dihydrochloride
US4052400A (en) * 1976-10-29 1977-10-04 Morton-Norwich Products, Inc. Hypertensive 1-substituted 2(1h)-pyrimidones

Also Published As

Publication number Publication date
ZA8164B (en) 1982-03-31
CA1168239A (en) 1984-05-29
ATE4715T1 (de) 1983-10-15
JPS56150087A (en) 1981-11-20
DE3160886D1 (en) 1983-10-27
DK3281A (da) 1981-07-08
US4399140A (en) 1983-08-16
ES8304946A1 (es) 1983-03-16
IE810013L (en) 1981-07-07
ES498337A0 (es) 1982-06-01
EP0032131A1 (en) 1981-07-15
NZ195947A (en) 1983-09-02
IE50765B1 (en) 1986-07-09
AU6601681A (en) 1981-07-16
ES509219A0 (es) 1983-03-16
EP0032131B1 (en) 1983-09-21
DK149892B (da) 1986-10-20
AU543939B2 (en) 1985-05-09
NO810024L (no) 1981-07-08

Similar Documents

Publication Publication Date Title
ES8101067A1 (es) Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
ES482134A1 (es) Un procedimiento para preparar derivados de 1-(3-mercapto- 2-metilpropanoil)-prolil-aminoacido.
ES8205782A1 (es) Procedimiento para la preparacion de pirimidin-2-sulfuros y sus s-oxidos
DE3160886D1 (en) 5-halo-pyrimidin-2-ones, the salts thereof, processes for their preparation and pharmaceutical compositions containing them
ES481729A1 (es) Procedimiento para la preparacion de derivados de 1,2-dihi- droquinolein-2-onas.
SE340459B (es)
ES8800254A1 (es) Procedimiento para la obtencion de nuevos derivados de la pristinamicina iib.
ES8307758A1 (es) "un procedimiento para la preparacion de pirimidin-2-onas sustituidas".
ES8401755A1 (es) Procedimiento para la preparacion de derivados de tiometilpiridina.
ES8202003A1 (es) Un procedimiento para la preparacion de derivados de ergoli-na
ES476354A1 (es) Procedimientos para la obtencion de nuevos derivados de ari-laminoimidazolina.
ES8300750A1 (es) Un procedimiento para la preparacion de pirimidin-2-onas sustituidas
HUP0203696A2 (hu) Sejtburjánzásgátló hatású helyettesített bisz-indolil-maleimidek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES8401461A1 (es) Procedimiento para la preparacion de derivados de 2-pirrolin-3-carbonitrilo.
ES428535A1 (es) Un procedimiento para la preparacion de cicloserina n-sus- tituida.
ES443559A1 (es) Un procedimiento para la obtencion de derivados de alanina -n,n-disustituidos.
ES450211A1 (es) Procedimiento para la obtencion de nuevos derivados de la 1-hidroxi-benzo-2,3,1-diazaborina.
ES356259A1 (es) Un procedimiento para la preparacion de compuestos hetero- ciclicos de actividad terapeutica.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19871118